Nathan Kapata1,2,3, Grace Mbulo4, Frank Cobelens5, Petra de Haas4,6, Ab Schaap4, Pike Mwamba4, Winnie Mwanza4, Mweemba Muvwimi1, Monde Muyoyeta4, Maureen Moyo4, Lutinala Mulenga1, Martin P Grobusch3, Peter Godfrey-Faussett6, Helen Ayles4,6. 1. Ministry of Health, Lusaka, Zambia. 2. National TB and Leprosy Control Programme, Lusaka, Zambia. 3. Center for Tropical Medicine and Travel Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 4. Zambia AIDS Related Tuberculosis Project, Lusaka, Zambia. 5. Department of Global Health, Amsterdam Institute of Global Health and Development, Academic Medical Centre, Amsterdam, The Netherlands. 6. Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.
Abstract
OBJECTIVE: The prevalence of MDR-TB in Zambia was estimated to be 1.8% in 2001. A second drug resistance survey was conducted in 2008 to determine trends; the use of the Genotype MTBDRplus assay was applied to compare results to the gold standard. METHOD: A two-stage cluster sampling, with health facilities as primary sampling units. Processed sputum specimens were inoculated on solid media for culture; heat-inactivated bacterial suspensions from sputum samples were tested on a commercial line probe assay for the identification of rifampicin and isoniazid resistance. RESULTS: A total of 917 patients with TB were enrolled and 883 (96.3%) analysed. A total of 574 (65%) had LJ results and 824 (93.3%) had results from MTBDRplus assay. The median age was 32, and 63.3% were males. MDR-TB according to LJ-based DST was 1.1% (CI 0.1-2.4) whereas according to MDTBDRplus assay was 1.6% (CI 0.6-2.6). Isoniazid monoresistance in new cases was 2.4% (CI 0.613-4.26) based on LJ results and 5.0% (CI 3.2-6.7) based on the MTBDRplus; in retreatment cases, it was 4.4% (CI 0.3-8.6) and 2.40% (CI <0.1-5.1) on LJ and MTBDRplus, respectively. Rifampicin monoresistance in new cases was 0.1% (CI <0.1-0.4) based on LJ and 0.6% (CI 0.01-1.1) based on the MTBDRplus; in retreatment cases, it was 0% (CI 0-3.8) and 1.8% (CI <0.1-4.0) on LJ and MTBDRplus, respectively. There were no XDR-TB cases found and no association between MDR-TB and HIV. CONCLUSION: There was no increase in MDR-TB prevalence in Zambia from 2001 to 2008; results from the two methods were similar. Molecular methods were quicker and simpler to use.
OBJECTIVE: The prevalence of MDR-TB in Zambia was estimated to be 1.8% in 2001. A second drug resistance survey was conducted in 2008 to determine trends; the use of the Genotype MTBDRplus assay was applied to compare results to the gold standard. METHOD: A two-stage cluster sampling, with health facilities as primary sampling units. Processed sputum specimens were inoculated on solid media for culture; heat-inactivated bacterial suspensions from sputum samples were tested on a commercial line probe assay for the identification of rifampicin and isoniazid resistance. RESULTS: A total of 917 patients with TB were enrolled and 883 (96.3%) analysed. A total of 574 (65%) had LJ results and 824 (93.3%) had results from MTBDRplus assay. The median age was 32, and 63.3% were males. MDR-TB according to LJ-based DST was 1.1% (CI 0.1-2.4) whereas according to MDTBDRplus assay was 1.6% (CI 0.6-2.6). Isoniazid monoresistance in new cases was 2.4% (CI 0.613-4.26) based on LJ results and 5.0% (CI 3.2-6.7) based on the MTBDRplus; in retreatment cases, it was 4.4% (CI 0.3-8.6) and 2.40% (CI <0.1-5.1) on LJ and MTBDRplus, respectively. Rifampicin monoresistance in new cases was 0.1% (CI <0.1-0.4) based on LJ and 0.6% (CI 0.01-1.1) based on the MTBDRplus; in retreatment cases, it was 0% (CI 0-3.8) and 1.8% (CI <0.1-4.0) on LJ and MTBDRplus, respectively. There were no XDR-TB cases found and no association between MDR-TB and HIV. CONCLUSION: There was no increase in MDR-TB prevalence in Zambia from 2001 to 2008; results from the two methods were similar. Molecular methods were quicker and simpler to use.
Authors: Nathan Kapata; Martin P Grobusch; Gershom Chongwe; Pascalina Chanda-Kapata; William Ngosa; Mathias Tembo; Shebba Musonda; Patrick Katemangwe; Matthew Bates; Peter Mwaba; Alimuddin Zumla; Frank Cobelens Journal: Infection Date: 2017-08-04 Impact factor: 3.553
Authors: Knut A Hestad; Jonathan Chinyama; Menon J Anitha; Mary S Ngoma; J Allen McCutchan; Donald R Franklin; Robert K Heaton Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Mary Kagujje; Paul Somwe; Sisa Hatwiinda; Joel Bwalya; Tamala Zgambo; Moomba Thornicroft; Fiammetta Maria Bozzani; Clement Moonga; Monde Muyoyeta Journal: BMJ Open Date: 2021-09-27 Impact factor: 3.006
Authors: Ruvandhi R Nathavitharana; Patrick G T Cudahy; Samuel G Schumacher; Karen R Steingart; Madhukar Pai; Claudia M Denkinger Journal: Eur Respir J Date: 2017-01-18 Impact factor: 16.671
Authors: Ariadna Rando-Segura; María Luisa Aznar; María Milagros Moreno; Mateu Espasa; Elena Sulleiro; Cristina Bocanegra; Eva Gil; Arlete N E Eugénio; Carlos Escartin; Adriano Zacarias; Josep Vegue; Domingos Katimba; María Carmen Vivas; Estevao Gabriel; María Concepción Marina; Jacobo Mendioroz; María Teresa López; Tomas Pumarola; Israel Molina; María Teresa Tórtola Journal: Emerg Infect Dis Date: 2018-03 Impact factor: 6.883
Authors: Mazhgan Rowneki; Naomi Aronson; Peicheng Du; Paige Sachs; Robert Blakemore; Soumitesh Chakravorty; Shawn Levy; Angela L Jones; Geetika Trivedi; Sheilla Chebore; Dennis Addo; Denis K Byarugaba; Panganani Dalisani Njobvu; Frederick Wabwire-Mangen; Bernard Erima; Eric S Ramos; Carlton A Evans; Braden Hale; James D Mancuso; David Alland Journal: PLoS One Date: 2020-05-08 Impact factor: 3.240
Authors: Patrick Lungu; Andrew D Kerkhoff; Clara C Kasapo; Judith Mzyece; Sulani Nyimbili; Rhehab Chimzizi; Andrew Silumesii; Mary Kagujje; Ramnath Subbaraman; Monde Muyoyeta; Kennedy Malama Journal: BMJ Open Date: 2021-08-10 Impact factor: 2.692
Authors: N Ruswa; F Mavhunga; J C Roscoe; A Beukes; E Shipiki; J van Gorkom; S Sawadogo; S Agolory; H Menzies; D Tiruneh; B Makumbi; B Bayer; A Zezai; P Campbell; H Alexander; N Kalisvaart; N Forster Journal: Int J Tuberc Lung Dis Date: 2019-07-01 Impact factor: 2.373